RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

Biomatrica launches DNAgard Blood and DNAstable Blood sample stabilization products

Biomatrica Inc., the leader in room temperature biological sample stabilization, today announced the release of DNAgard® Blood and DNAstable® Blood.

22 Sep 2010

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.

22 Sep 2010

Synthetic lethality boosts effectiveness of molecularly targeted therapies against tumors

Molecularly targeted therapies can reduce tumors rapidly. However, not all tumors respond to the drugs, and even those that do often develop resistance over time. Looking for a way to combat the problem of resistance, researchers at Fox Chase Cancer Center hypothesized that hitting already weakened cancer cells with a second targeted agent could kill them-but only if it was the right second agent.

22 Sep 2010

Study demonstrates why targeted therapies do not work in majority of people

In order for targeted therapies against cancer to be effective, scientists need to understand upfront what related proteins in a signaling "network" makes a cancer cell resistant to a drug and selectively target them as well, say researchers at Georgetown Lombardi Comprehensive Cancer Center and Fox Chase Cancer Center.

22 Sep 2010

Optimer submits fidaxomicin rolling NDA for treatment of Clostridium difficile infection

Optimer Pharmaceuticals, Inc. today announced that it has submitted the first section of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for fidaxomicin to treat patients with Clostridium difficile infection (CDI) and to prevent recurrences of CDI. Optimer anticipates completing the submission in the fourth quarter of 2010 and plans to request priority review, which, if granted, could lead to an FDA decision on the NDA in the second quarter of 2011.

21 Sep 2010

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non-Responders (INR) after at least 24 months of highly active anti-retroviral therapy (HAART).

21 Sep 2010

Annals of Internal Medicine publishes GRACE study data on HIV therapy

Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of treatment experienced adult women with HIV-1 to examine gender differences in response to HIV therapy. Sponsored by Tibotec Therapeutics Clinical Affairs, a division of Centocor Ortho Biotech Services, LLC, the GRACE study enrolled 67 percent women, demonstrating that it is possible to recruit large numbers of women into U.S.-based HIV treatment studies.

21 Sep 2010

Researchers discover HIV-1 resists AZT drug

Rutgers researchers have discovered how HIV-1, the virus that causes AIDS, resists AZT, a drug widely used to treat AIDS. The scientists, who report their findings in Nature Structural & Molecular Biology, believe their discovery helps researchers understand how important anti-AIDS treatments can fail and could help AIDS researchers develop more effective treatment for the disease.

20 Sep 2010

Scientists develop computer model to examine genetic switch for TB dormancy

An examination of a portion of the tuberculosis genome that responds to stress has allowed Rice University bioengineers Oleg Igoshin and Abhinav Tiwari to zero in on a network of genes that may "switch" the disease into dormancy.

18 Sep 2010

Conference to discuss frontline of immunological research, its clinical application

The immune system is evolved to protect our body against a variety of infectious agents which can cause serious and often fatal diseases. We now appreciate that the immune system is also involved in surveillance of malignant transformation of normal cells that constitute our body, as well as rejection of transplanted organs.

17 Sep 2010

Blood vessel growth promoting microRNA predicts diabetes: Study

For the first time, scientists have found that blood levels of some ribonucleic acids (microRNAs) are different among people with type 2 diabetes and those who subsequently develop the disease compared to healthy controls, according to research reported in Circulation Research: Journal of the American Heart Association.

17 Sep 2010

New genetic analysis technique isolates culprit gene in families with inherited single-gene kidney diseases

A University of Michigan-led research team has identified a gene responsible in some families for a devastating inherited kidney disorder, thanks to a new, faster method of genetic analysis not available even two years ago. The success offers hope that scientists can speed the painstaking search for the genes responsible for many rare diseases and test drugs to treat them.

17 Sep 2010

Scripps Research Institute receives grant to develop DNA sequencing technology

Scripps Research Institute Professor Reza Ghadiri, Ph.D., has been awarded a four-year, $5.1 million grant as part of a National Institutes of Health (NIH) initiative to spur the development of the next generation of DNA sequencing technologies, which could enable biomedical researchers and health care workers to routinely sequence a person's DNA.

17 Sep 2010

NHLBI selects NuGEN to provide automated reagent solutions for expression profiling

NuGEN Technologies, the provider of innovative RNA and DNA amplification and sample preparation technologies for genomic analysis, today announced it has been selected by the National Heart, Lung, and Blood Institute (NHLBI) to provide automated reagent solutions for expression profiling of approximately 6,000 blood samples from the Framingham Heart Study.

16 Sep 2010

NEB receives SBIR funding to develop novel enzymatic reagents for epigenetic studies

New England Biolabs (NEB) has announced that it has received fast track SBIR funding of $1.22 million to fund the research and development of novel enzymatic reagents for epigenetic studies.

From New England Biolabs 16 Sep 2010

Researchers identify interferons may inhibit IL-1b protein production

Among the first is the production of cell factors such as interferons and IL-1beta. Interferons have several functions, including activating a series of intracellular signals such as Tyk2 (Tyrosine kinase 2), while IL-1beta is important for the induction of inflammation, which helps directly to protect the body against attack.

16 Sep 2010

Abstract on ACH-1625 accepted as late breaking poster presentation at The Liver Meeting 2010

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that its abstract titled "ACH-1625 Demonstrates Sustained Viral Suppression in Presence of Uncommon Drug Resistant HCV Variants: Pharmacokinetic, Pharmacodynamic and Clinical Virology Analysis of Phase I Study" has been accepted as a late breaking poster presentation at the 61st Annual Meeting of the American Association for the Study of Liver Disease The Liver Meeting 2010 being held October 29-November 2, 2010 in Boston.

15 Sep 2010

COTI selected for Canadian life sciences partnering mission

Critical Outcome Technologies Inc. announced today that the Company was selected by the Consulate General of Canada and BIOTECanada to attend a life sciences partnering mission in Boston, MA. This initiative is being held in conjunction with the BioPharm America conference taking place September 15-17, 2010.

15 Sep 2010

Norgen Biotek launches three novel kits for urine sampling

Norgen Biotek Corp, a privately held Canadian biotechnology company focusing principally on advancing a powerful proprietary technology for application in sample preparation for nucleic acid (DNA, RNA and microRNA) and protein purification, today announced the expansion of its basket of urine-based sample preparation products by launching 3 new urine concentration, preservation and isolation kits.

15 Sep 2010

Optimer Pharmaceuticals to present fidaxomicin Phase 3 clinical trial data at ICAAC Conference

Optimer Pharmaceuticals, Inc. announced the presentation of new data from its North American and European fidaxomicin Phase 3 clinical trials in patients with Clostridium difficile infection (CDI) at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston.

15 Sep 2010

RNA News and Research

Further Reading

Biomatrica launches DNAgard Blood and DNAstable Blood sample stabilization products

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Synthetic lethality boosts effectiveness of molecularly targeted therapies against tumors

Study demonstrates why targeted therapies do not work in majority of people

Optimer submits fidaxomicin rolling NDA for treatment of Clostridium difficile infection

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Annals of Internal Medicine publishes GRACE study data on HIV therapy

Researchers discover HIV-1 resists AZT drug

Scientists develop computer model to examine genetic switch for TB dormancy

Conference to discuss frontline of immunological research, its clinical application

Blood vessel growth promoting microRNA predicts diabetes: Study

New genetic analysis technique isolates culprit gene in families with inherited single-gene kidney diseases

Scripps Research Institute receives grant to develop DNA sequencing technology

NHLBI selects NuGEN to provide automated reagent solutions for expression profiling

NEB receives SBIR funding to develop novel enzymatic reagents for epigenetic studies

Researchers identify interferons may inhibit IL-1b protein production

Abstract on ACH-1625 accepted as late breaking poster presentation at The Liver Meeting 2010

COTI selected for Canadian life sciences partnering mission

Norgen Biotek launches three novel kits for urine sampling

Optimer Pharmaceuticals to present fidaxomicin Phase 3 clinical trial data at ICAAC Conference

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo